Response: Intrathecal methotrexate and central nervous system events.
Schmitz
Norbert
N
Zeynalova
Samira
S
Loeffler
Markus
M
Pfreundschuh
Michael
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007278:Injections, Spinal / Q000379:methods*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D012107:Research Design; D012306:Risk; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate